Statements (53)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:activities |
inhibits growth hormone release
|
gptkbp:availability |
prescription only
|
gptkbp:category |
minimal
Category B |
gptkbp:class |
endocrine therapy
somatostatin analogue |
gptkbp:clinical_trial |
Phase III
long-term management |
gptkbp:community_service |
not established
|
gptkbp:contraindication |
hypersensitivity to octreotide
|
gptkbp:dosage_form |
sustained-release injection
|
gptkbp:education |
instruct on injection technique
|
gptkbp:effective_date |
gptkb:2003
FDA approved |
gptkbp:formulation |
powder for suspension
|
gptkbp:frequency |
once every 4 weeks
|
https://www.w3.org/2000/01/rdf-schema#label |
Sandostatin LAR
|
gptkbp:indication |
treatment of neuroendocrine tumors
|
gptkbp:ingredients |
gptkb:octreotide
|
gptkbp:interacts_with |
may interact with insulin
|
gptkbp:is_atype_of |
H01 C B02
|
gptkbp:is_monitored_by |
monitor glucose levels
|
gptkbp:is_used_for |
acromegaly
VI Poma carcinoid syndrome |
gptkbp:lifespan |
2 hours
|
gptkbp:manager |
intramuscular injection
|
gptkbp:manufacturer |
gptkb:Novartis
|
gptkbp:marketed_as |
Sandostatin LAR Depot
|
gptkbp:packaging |
vial
|
gptkbp:pharmacokinetics |
bioavailability varies with route
|
gptkbp:price |
varies by region
|
gptkbp:products |
lanreotide
pasireotide |
gptkbp:provides_information_on |
included in treatment protocols for acromegaly
|
gptkbp:requires |
gptkb:theorem
|
gptkbp:research |
ongoing for efficacy in other conditions
|
gptkbp:rounds |
hepatic metabolism
|
gptkbp:safety_features |
monitor for gallbladder disease
|
gptkbp:scholarships |
available through manufacturer programs
|
gptkbp:shelf_life |
24 months
|
gptkbp:side_effect |
fatigue
headache nausea abdominal pain diarrhea gastrointestinal disturbances |
gptkbp:social_structure |
C49 H66 N10 O10 S
|
gptkbp:storage |
store at 2-8° C
|
gptkbp:technique |
deep intramuscular injection
|
gptkbp:bfsParent |
gptkb:octreotide
|
gptkbp:bfsLayer |
7
|